In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK1,025.00. The company’s shares closed yesterday ...

Novo Nordisk continues to witness strong growth across its portfolio of diabetes and obesity care medications. The company's tailwinds include expanded indications and new geographic markets.

Over the last couple of years, Danish company Novo Nordisk (NYSE: NVO) has evolved from a relatively obscure pharmaceutical business to perhaps the biggest rising star in healthcare. The company's ...

Novo Nordisk (NVO) has released an update. Don't Miss our Black Friday Offers: Novo Nordisk has initiated a significant share repurchase program, aiming to buy back up to DKK 20 billion worth of B ...

The world’s largest philanthropic fund that ultimately controls Novo Nordisk A/S will ramp up its investments outside of Denmark after cashing in on the weight-loss drug boom. The Novo Nordisk ...

With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key step in unlocking a big, fast-growing market for its blockbuster franchise.

COPENHAGEN (Reuters) -Shares of Danish weight-loss drug maker Novo Nordisk rose 1.3% on Tuesday as U.S. President Joe Biden ...